Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

• Status: Completed
• Trial end date: 2016-05-05
• Target enrollment: 0
• Participant gender: Male

Summary

A phase I absolute bioavailability study of BMS-626529 following oral and intravenous dosing

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: ViiV Healthcare
• Collaborator: GlaxoSmithKline
• Treatments: Fostemsavir

Criteria

Inclusion Criteria:

• Generally healthy

• BMI 18.0-32.0 kg/m2

• Men sexually active with women of childbearing potential must follow instructions for contraception for the duration of treatment plus 90 days

• Men must refrain from sperm donation for the length of the study and for 90 days

• Sign informed consent

Exclusion Criteria:

• Significant medical illness

• Tobacco use in the last 12 months

• Major surgery within 4 weeks of study administration

• Donation of blood within 4 weeks of study administration

• Current or recent (within 3 months of study administration) of gastrointestinal disease